| scholarly article | Q13442814 |
| P2093 | author name string | Mondher Toumi | |
| Martin Knapp | |||
| Traolach Brugha | |||
| Clement Francois | |||
| Stephen Almond | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | quality of life | Q13100823 |
| schizophrenia | Q41112 | ||
| P304 | page(s) | 346-351 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | British Journal of Psychiatry | Q4035428 |
| P1476 | title | Relapse in schizophrenia: costs, clinical outcomes and quality of life | |
| P478 | volume | 184 |
| Q39292758 | A randomized controlled trial comparing self-referral to inpatient treatment and treatment as usual in patients with severe mental disorders |
| Q44722660 | Adherence to Antipsychotic Drug Measured by an Arabic Version of Morisky Scale. |
| Q45246308 | Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. |
| Q50066712 | All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics |
| Q90366283 | An Economic Evaluation of Coordinated Specialty Care (CSC) Services for First-Episode Psychosis in the U.S. Public Sector |
| Q34102285 | An estimate of the monthly cost of two major mental disorders in an Indian metropolis |
| Q39206700 | Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia |
| Q100548695 | Are adult stressful life events associated with psychotic relapse? A systematic review of 23 studies |
| Q57825253 | Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective |
| Q38728652 | Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia |
| Q38851847 | Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. |
| Q35841195 | Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study |
| Q58096934 | Capturing Rest-Activity Profiles in Schizophrenia Using Wearable and Mobile Technologies: Development, Implementation, Feasibility, and Acceptability of a Remote Monitoring Platform |
| Q55324826 | Claims-based proxies of patient instability among commercially insured adults with schizophrenia. |
| Q34560335 | Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. |
| Q37711124 | Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment |
| Q39303150 | Comparing early signs and basic symptoms as methods for predicting psychotic relapse in clinical practice. |
| Q41396429 | Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics |
| Q46896756 | Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? |
| Q51919545 | Cost of schizophrenia: direct costs and use of resources in the State of São Paulo. |
| Q34109190 | Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study |
| Q50794265 | Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. |
| Q36573896 | Cost-effectiveness of atypical antipsychotic medications versus conventional medication |
| Q36581690 | Cost-of-illness studies : a review of current methods. |
| Q38675225 | Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics |
| Q46896765 | Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany |
| Q33363460 | Costs of treating patients with schizophrenia who have illness-related crisis events |
| Q33589087 | Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review |
| Q36096550 | Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. |
| Q64103876 | Development and Long-Term Acceptability of ExPRESS, a Mobile Phone App to Monitor Basic Symptoms and Early Signs of Psychosis Relapse |
| Q46689236 | Direct transition to long-acting risperidone--analysis of long-term efficacy |
| Q50617008 | Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment |
| Q104485905 | Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study |
| Q47628290 | Early psychosis intervention outpatient service of the 1st Psychiatric University Clinic in Athens: 3 Years of experience |
| Q83696423 | Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia |
| Q98944172 | Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia |
| Q93153645 | Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies |
| Q36445106 | Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model |
| Q64913060 | Feasibility of using a smartphone app to assess early signs, basic symptoms and psychotic symptoms over six months: A preliminary report. |
| Q90173301 | Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study |
| Q37609382 | Impact of antipsychotic medication on the cost of schizophrenia |
| Q55556616 | Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. |
| Q48534531 | Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers |
| Q37418931 | Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic |
| Q37178608 | Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. |
| Q38114144 | Measuring quality of life in patients with schizophrenia:an overview |
| Q36765328 | Mobile.net: Mobile Telephone Text Messages to Encourage Adherence to Medication and to Follow up With People With Psychosis: Methods and Protocol for a Multicenter Randomized Controlled Two-Armed Trial |
| Q46896768 | Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada |
| Q41263542 | Multifamily psychoeducation for first-episode psychosis: a cost-effectiveness analysis |
| Q37809849 | Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia |
| Q37076234 | Outpatient antipsychotic treatment and inpatient costs of schizophrenia |
| Q45384257 | Perceived risk of relapse and role of medication: comparison between patients with psychosis and their caregivers. |
| Q36370291 | Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models |
| Q38680307 | Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. |
| Q36249889 | Predictors of long term use of psychiatric services of patients with recent-onset schizophrenia: 12 years follow-up |
| Q34990923 | Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study |
| Q33709704 | Predictors of switching antipsychotic medications in the treatment of schizophrenia |
| Q34830869 | Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis |
| Q33814003 | Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. |
| Q36169820 | Psychotic relapse and associated factors among patients attending health services in Southwest Ethiopia: a cross-sectional study. |
| Q34467748 | Qualitative investigation of targets for and barriers to interventions to prevent psychosis relapse |
| Q34542824 | Quality of life is predictive of relapse in schizophrenia |
| Q42839514 | Relapse in long-term conditions: learning from mental health methods |
| Q53701232 | Relapse prediction in schizophrenia through digital phenotyping: a pilot study. |
| Q56790547 | Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA |
| Q51907745 | Relapse rates in an early psychosis treatment service. |
| Q37300932 | Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study |
| Q47154075 | Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia |
| Q26752965 | Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life |
| Q51925514 | Self-perceived health status of schizophrenic patients in Spain: analysis of geographic differences. |
| Q46226224 | Socio-economic correlates of relapsed patients admitted in a Nigerian mental health institution |
| Q38061501 | Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. |
| Q38751617 | The Correlates of Quality of Life Among Jordanian Patients With Schizophrenia. |
| Q38769604 | The Cost of Relapse in Schizophrenia. |
| Q47551032 | The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia |
| Q89746518 | The association between community mental health nursing and hospital admissions for people with serious mental illness: a systematic review |
| Q38089699 | The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations |
| Q33522776 | The cost of relapse and the predictors of relapse in the treatment of schizophrenia |
| Q51866468 | The cost of relapse in schizophrenia and schizoaffective disorder. |
| Q42659773 | The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia |
| Q40157100 | The effectiveness of discharge planning on the knowledge, clinical symptoms and hospitalisation frequency of persons with schizophrenia: a longitudinal study in two hospitals in Tehran, Iran. |
| Q35327044 | The management of schizophrenia: focus on extended-release quetiapine fumarate |
| Q37111828 | The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy |
| Q34418847 | The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. |
| Q37960512 | Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia |
| Q50982700 | Towards a pragmatic and operational definition of relapse in schizophrenia: A Delphi consensus approach. |
| Q36169091 | Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia |
| Q38279578 | Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics |
| Q33984835 | Two-year prospective case-controlled study of a case management program for community-dwelling individuals with schizophrenia |
| Q52303292 | [Relapse: causes and consequences]. |
Search more.